Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
Akebia Therapeutics (AKBA) and the Path to Its $3.90 Average Analyst Target

Akebia Therapeutics (AKBA) and the Path to Its $3.90 Average Analyst Target

Key Takeaways

  • The central $3.90 target represents the arithmetic mean of five verified analyst price targets rather than any single firm’s forecast.
  • From a recent close near $0.76, reaching $3.90 would require a gain of roughly 410%, a substantial move.
  • The target range spans from $1.00 (Leerink Partners, Hold) to $6.00 (H.C. Wainwright, Buy), highlighting significant disagreement on execution risk.
  • Key supports include Vafseo commercialization, the kidney-disease pipeline, and a European licensing deal.
  • Major risks center on the sub-$1 share price, revenue-recognition issues, and Nasdaq listing compliance concerns.

Analyst Price Targets and the Consensus Picture

Akebia Therapeutics, Inc. (AKBA) focuses on developing and commercializing kidney-disease treatments, with Vafseo (vadadustat) for dialysis-related anemia and Auryxia (ferric citrate) as its main products. I reviewed five current analyst targets: Piper Sandler’s Buy rating at $4.00 (October 2026), BTIG’s Buy at $4.00 (September 2026), WestPark Capital’s Buy at $4.50 (September 2026), Leerink Partners’ Hold at $1.00 (August 2026), and H.C. Wainwright’s Buy at $6.00 (August 2026). The arithmetic mean comes to $3.90 within that wide $1.00-to-$6.00 band.

The spread itself reveals the underlying debate. Differing views on whether Vafseo revenue can scale consistently drive the gap between the cautious $1.00 and optimistic $6.00 targets. While the overall ratings tilt bullish, the broad range suggests treating the average as a directional indicator rather than a precise prediction. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and the Scale of the Move

Shares closed near $0.76 in late October 2026, down about 80% over the past year and close to the 52-week low of roughly $0.54. A climb to $3.90 would demand an increase of approximately 410%, underscoring the magnitude involved. Market capitalization sits around $212 million, reflecting the compression the stock has experienced.

Any credible path to the target would likely hinge on sustained Vafseo revenue growth, progress in the praliciguat Phase 2 program for focal segmental glomerulosclerosis, and restored investor confidence after the US Renal Care dosing-protocol change disrupted recognized revenue. Recovery would probably occur through successive re-ratings rather than one decisive event.

Factors That Could Support Progress Toward the Target

The bull case centers on execution. Vafseo targets a sizable dialysis-anemia market, and the most recent quarter showed revenue near $49 million alongside a narrowed net loss of about $9 million. A licensing agreement with Medice extends the commercial reach into Europe, while the praliciguat program adds pipeline flexibility. Insider buying and a mostly Buy-rated analyst group suggest some professionals see meaningful upside from current levels.

Obstacles That Could Keep the Target Out of Reach

Challenges remain significant. Trading below $1 raises structural concerns, and data from Fidelity indicates the company has not met Nasdaq continued-listing requirements. The dosing-protocol adjustment at US Renal Care has created uncertainty around near-term Vafseo sales. Prior target reductions and the latest GAAP net loss reinforce that consistent revenue growth and a clearer route to profitability must come first before a move of this size becomes realistic.

Technical Levels Worth Watching

The stock remains in a clear downtrend after hitting the 52-week low near $0.54 and rebounding to about $0.76. The $1.00 level stands out as both a psychological threshold and a key marker tied to listing status and Leerink’s target. Nearer-term resistance appears in the $0.80–$0.90 zone, while any advance toward $3.90 would need to clear much higher levels without recent price history for reference.

Time Horizon and Items to Monitor

Analyst targets generally reflect a roughly 12-month horizon. Investors should track quarterly Vafseo revenue trends and any additional commentary on the dosing-protocol impact, updates from the praliciguat Phase 2 trial, cash position and financing moves, and progress on Nasdaq compliance. Revisions to price targets, especially further cuts or upgrades, will indicate whether the $1.00-to-$6.00 range is tightening.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions and technical patterns. I find these signals helpful for spotting shifts that complement fundamental analysis like the factors discussed here. For those following AKBA, layering the signals onto the revenue and pipeline details can provide additional day-to-day context.

Final Assessment

Can AKBA reach $3.90? The target is genuine yet demanding: it averages five analyst forecasts but sits roughly 410% above the recent price, and the $1.00-to-$6.00 spread shows deep differences in outlook. The supporting elements—Vafseo commercialization, pipeline assets, and the European partnership—are real, yet they face offsets from the sub-$1 price, revenue disruption, and listing concerns. Achieving the target would require a sustained re-rating that has not yet materialized. Investors should view the figure as a long-term, high-risk scenario and focus on revenue consistency, pipeline developments, financing, and analyst updates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AKBA

AKBA sees MACD Histogram crosses below signal line

AKBA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 38 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBA as a result. In 63 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for AKBA entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AKBA's RSI Oscillator exited the oversold zone, 32 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 223 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.445) is normal, around the industry mean (6.379). P/E Ratio (-3.344) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (183.387).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -3%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -11%. AKAN experienced the highest price growth at 449%, while BFRI experienced the biggest fall at -36%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 57%. For the same stocks of the Industry, the average monthly volume growth was 60% and the average quarterly volume growth was 91%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 82
Seasonality Score: 5 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of drugs for the treatment of anemia and vascular diseases

Industry PharmaceuticalsGeneric

Industry
Biotechnology
Address
245 First Street
Phone
+1 617 871-2098
Employees
194
Web
https://www.akebia.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.